- Details
- Rashid Sayyid and Zachary Klaassen discuss the 2024 NCCN prostate cancer guideline updates for systemic therapy in metastatic hormone-sensitive prostate cancer (mHSPC). They highlight the new stratification of treatment recommendations based on disease volume and timing of metastases. The discussion covers recent clinical trials supporting triplet therapy for high-volume synchronous disease, inclu...
|
- Details
- Rashid Sayyid and Zach Klaassen review the 2024 NCCN prostate cancer guideline updates focusing on treatment-related bone loss in patients on androgen deprivation therapy (ADT). They emphasize the importance of addressing bone health due to increased fracture risk associated with ADT. The speakers outline a comprehensive approach to bone health management, including risk assessment using the FRAX...
|
- Details
- Rashid Sayyid and Zach Klaassen review the NCCN prostate cancer guideline updates regarding the prevention of symptomatic skeletal-related events in bone metastatic CRPC patients. They discuss the efficacy and safety profiles of denosumab and zoledronic acid, highlighting key clinical trials that have shaped current recommendations. The speakers emphasize the importance of considering dosing frequ...
|
- Details
- Rashid Sayyid and Zachary Klaassen discuss the 2024 updates to the NCCN guidelines for metastatic castration-resistant prostate cancer (mCRPC) treatment. They review the current management algorithm, emphasizing the importance of confirming castrate status and proper staging. The presentation covers treatment options for adenocarcinoma and small cell/neuroendocrine variants, highlighting the signi...
|
- Details
- Rashid Sayyid and Zach Klaassen review the 2024 NCCN Guidelines for managing very low-risk prostate cancer. Dr. Sayyid defines very low-risk prostate cancer using criteria like T1C stage, PSA levels, and biopsy characteristics. The updated guidelines simplify management based on life expectancy: patients with 10 years or more are recommended active surveillance, while those with less are advised o...
|
- Details
- Rashid Sayyid and Zach Klaassen explore the significant updates to the 2024 NCCN guidelines for prostate cancer, focusing on the integration of relugolix for metastatic castration-sensitive prostate cancer (M1-CSPC). Dr. Sayyid highlights the HERO trial, which established relugolix as an effective oral GnRH antagonist with rapid and sustained testosterone suppression, outperforming leuprolide in b...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the 2024 updates to the NCCN Prostate Cancer Guidelines. They focus on non-hormonal systemic therapy, highlighting significant changes, particularly the emergence of PARP inhibitors like olaparib and rucaparib. The discussion covers their monotherapy and combination therapies, emphasizing the stronger endorsement for PARP inhibitors in patients with BRCA mut...
|
- Details
- Rashid Sayyid and Zach Klaassen dive into the 2024 updates of the NCCN prostate cancer guidelines, specifically addressing the treatment and monitoring of progressive M0 CSPC in patients post-maximal pelvic therapy. Highlighting the critical nature of identifying high-risk patients, they introduce the major shift in recommendations based on the EMBARK trial results, which supports considering enza...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the 2024 updates to the NCCN Prostate Cancer Guidelines, highlighting the integration of the Decipher Genomic Classifier tests across various stages of prostate cancer management. This detailed conversation explores the progression from the 2023 guidelines, emphasizing the evolution of risk stratification tools from prognostic to the now predictive capabilit...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the 2024 updates to the NCCN Prostate Cancer Guidelines, highlighting the emergence of the ArteraAI Prostate Test for risk stratification in prostate cancer management. This innovative test, now considered a predictive model, marks a significant advance, providing more accurate risk assessments for biochemical recurrence, distant metastasis, and prostate can...
|
